Dr Brad Gessner | Vice President, Medical And Scientific Affairs, Amp; Vice President, Global Medical Lead For Pneumococcal Vaccines
Pfizer

Dr Brad Gessner, Vice President, Medical And Scientific Affairs, Amp; Vice President, Global Medical Lead For Pneumococcal Vaccines, Pfizer

Dr. Gessner is currently Vice President and Global Medical Lead for Pneumococcal Vaccines at Pfizer Vaccines, a position he has held since December 2016. He also maintains an affiliation as an adjunct professor at the University of Maryland and serves on the Board of Agence de Medicine Preventive (AMP). Before joining Pfizer, he served as the Scientific Director and Chief Scientific Officer at AMP for 20 years, and started and developed the Maternal and Child Health Epidemiology Unit at the Alaska Division of Public Health. Dr. Gessner completed pediatric and preventive medicine residencies, an MPH, and a CDC Epidemic Intelligence Service fellowship. He has authored over 220 peer-reviewed manuscripts primarily on vaccines and vaccine preventable diseases from studies conducted in 30 different countries. He has served on WHO's IVIR-AC and IPAC expert committees, several SAGE working groups, and on the Gavi Board. 
 

Appearances:



April 14 Pre-congress Workshop Day @ 10:00

WORKSHOP C: MARKET ACCESS

Market access & regulatory challenges in vaccinesThe market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines. Learn how get optimal value for our vaccines and avoid the pit falls when launching a new vaccine.
  • What to do about Vaccine Hesitancy: When the “Facts” and the “Truth” are Discordant
  • Accurately capturing the full benefits of vaccines
  • HTA assessments around the world: What are the key attributes that drive decisions?
  • Regulatory and public health approaches to clinical trial design and interpretation
  • Value based contracting and managed entry agreements – Making sure uncertainties at launch do not hinder market access
  • Industry perspective: Navigating market authorization applications and life cycle management for new vaccines
  • The Gavi Alliance approach to increasing vaccine access in low-income countries; targeting “Healthy Markets” for vaccines in low-income countries
  • Group discussion and Q&A with audience
last published: 11/Apr/19 16:05 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071